As an efficacious treatment for the HIV virus, the NRTI Lamivudine is now showing promise as a drug to combat age-related macular degeneration, known also as AMD. Nucleoside reverse transcriptase inhibitors, or NRTIs are the most commonly used class of anti-HIV medications and they are touted to successfully act on the enzyme reverse transcriptase, prohibiting[…]
NRTI Lamivudine Looks Promising for AMD Treatment
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: AMDHIV virus Jan 05, 2015
Aflibercept Touted as 2013 Blockbuster Drug
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AfliberceptAMDEuropean Commissionintraocular pressure Jan 08, 2014
Aflibercept, also known as brand name Eyelea, has been recently touted as a 2013 blockbuster drug. With sales of Aflibercept in the United States thought to have surpassed 1.3 billion dollars in the 2013 calendar year, the pharmaceutical community has been optimistically awaiting final year end data. Marketed by Regeneron in the U.S., Eyelea {Aflibercept}[…]
Aflibercept Is Proving to be a Diverse and Effectual Product
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AfliberceptAMDcolorectal cancer Mar 12, 2012
Clinical development of an exciting new recombinant fusion protein, Aflibercept, is underway. As an inhibitor of VEGF, or the vascular endothelial growth factor receptor, aflibercept is currently in a phase III trial for second line metastatic colorectal cancer. This trial for Aflibercept is being conducted by Sanofi-Aventis and Regeneron Pharmaceuticals. Additional trials currently in progress[…]
